KVV24301
Lake Victoria marburgvirus (MARV) Envelope glycoprotein (GP)
Colorimetric
Plasma, Serum
Quantitative
0.07 - 50 ng/mL
0.07 ng/mL
CV<15%
80-120%
2-8 ℃
The stability of ELISA kit is determined by the loss rate of activity. The loss rate of this kit is less than 10% prior to the expiration date under appropriate storage condition.
Potent neutralization of Marburg virus by a vaccine-elicited monoclonal antibody., PMID:40463027
Process Intensification for Recombinant Marburg Virus Glycoprotein Production Using Drosophila S2 Cells., PMID:40391203
Molecular virulence determinants of human-pathogenic filoviruses., PMID:40379380
MyosinVb tail inhibits transport of Marburg virus glycoprotein GP to VP40-enriched sites at the plasma membrane., PMID:40174331
Jamaican fruit bats' competence for Ebola but not Marburg virus is driven by intrinsic differences., PMID:40133326
From protein to immunology: comprehensive insights into Marburg virus vaccines, mechanism, and application., PMID:40025302
Rapid Development of Modified Vaccinia Virus Ankara (MVA)-Based Vaccine Candidates Against Marburg Virus Suitable for Clinical Use in Humans., PMID:39771978
A surrogate BSL2-compliant infection model recapitulating key aspects of human Marburg virus disease., PMID:39745141
Construction and evaluation of glycoprotein-based nucleic acid vaccines for Marburg virus., PMID:39607590
Serological Evidence of Potential Marburg Virus Circulation in Livestock and Dogs in Ghana., PMID:39599470
Quantification of Neutralizing Antibodies in Serum Using VSV-MARV-GFP., PMID:39585633
In Vivo Investigation of Filovirus Glycoprotein-Mediated Infection in a BSL2 Setting., PMID:39585622
Generation, Recovery, and Propagation of a Recombinant Vesicular Stomatitis Virus Expressing the Marburg Virus Glycoprotein., PMID:39585614
Lysosome-Associated Membrane Protein Targeting Strategy Improved Immunogenicity of Glycoprotein-Based DNA Vaccine for Marburg Virus., PMID:39340043
Longitudinal proteome-wide antibody profiling in Marburg virus survivors identifies wing domain immunogen for vaccine design., PMID:39285186
Rational design of self-amplifying virus-like vesicles with Ebola virus glycoprotein as vaccines., PMID:39217415
Vaccine Platform Comparison: Protective Efficacy against Lethal Marburg Virus Challenge in the Hamster Model., PMID:39126087
Design of a novel multi-epitope vaccine against Marburg virus using immunoinformatics studies., PMID:38970027
A Microsphere Immunoassay for the Quantitative Detection of Antigens in Cell Culture Supernatant., PMID:38951344
(+)-fenchol and (-)-isopinocampheol derivatives targeting the entry process of filoviruses., PMID:38889610
Divergent antibody recognition profiles are generated by protective mRNA vaccines against Marburg and Ravn viruses., PMID:38585993
Bioinformatic, Biochemical, and Immunological Mining of MHC Class I Restricted T Cell Epitopes for a Marburg Nucleoprotein Microparticle Vaccine., PMID:38543955
A novel MARV glycoprotein-specific antibody with potentials of broad-spectrum neutralization to filovirus., PMID:38526940
Production and Purification of Filovirus Glycoproteins., PMID:38315357
Thermostable bivalent filovirus vaccine protects against severe and lethal Sudan ebolavirus and marburgvirus infection., PMID:38158300
Designing a novel and combinatorial multi-antigenic epitope-based vaccine "MarVax" against Marburg virus-a reverse vaccinology and immunoinformatics approach., PMID:38012426
Transcriptional profiling of immune responses in NHPs after low-dose, VSV-based vaccination against Marburg virus., PMID:37616377
Contrasting effects of filamin A and B proteins in modulating filovirus entry., PMID:37585478
Immunoinformatic and reverse vaccinology-based designing of potent multi-epitope vaccine against Marburgvirus targeting the glycoprotein., PMID:37534001
Long-term Prophylaxis Against Aerosolized Marburg Virus in Nonhuman Primates With an Afucosylated Monoclonal Antibody., PMID:37474248
Preexisting Immunity Does Not Prevent Efficacy of Vesicular Stomatitis Virus-Based Filovirus Vaccines in Nonhuman Primates., PMID:37290042
The Inability of Marburg Virus to Cause Disease in Ferrets Is Not Solely Linked to the Virus Glycoprotein., PMID:37288605
A Highly Attenuated Panfilovirus VesiculoVax Vaccine Rapidly Protects Nonhuman Primates Against Marburg Virus and 3 Species of Ebola Virus., PMID:37171813
Structural and Energetic Basis for Differential Binding of Ebola and Marburg Virus Glycoproteins to a Bat-Derived Niemann-Pick C1 Protein., PMID:37119290
Computational Modeling and Evaluation of Potential mRNA and Peptide-Based Vaccine against Marburg Virus (MARV) to Provide Immune Protection against Hemorrhagic Fever., PMID:37101690
Pseudotyped Viruses for Marburgvirus and Ebolavirus., PMID:36920694
Rapid protection of nonhuman primates against Marburg virus disease using a single low-dose VSV-based vaccine., PMID:36774693
Chaperoning the driver of filovirus egress to a dead end., PMID:36763514
Ebola Virus Activates IRE1α-Dependent XBP1u Splicing., PMID:36680162
A rabies virus-vectored vaccine expressing two copies of the Marburg virus glycoprotein gene induced neutralizing antibodies against Marburg virus in humanized mice., PMID:36453198
Single-Shot ChAd3-MARV Vaccine in Modified Formulation Buffer Shows 100% Protection of NHPs., PMID:36423030
Nonhuman Primates Are Protected against Marburg Virus Disease by Vaccination with a Vesicular Stomatitis Virus Vector-Based Vaccine Prepared under Conditions to Allow Advancement to Human Clinical Trials., PMID:36298451
First-in-human study to evaluate safety, tolerability, and immunogenicity of heterologous regimens using the multivalent filovirus vaccines Ad26.Filo and MVA-BN-Filo administered in different sequences and schedules: A randomized, controlled study., PMID:36197845
Immune Correlates of Protection from Filovirus Efficacy Studies in Non-Human Primates., PMID:36016226
Protection against Marburg Virus and Sudan Virus in NHP by an Adenovector-Based Trivalent Vaccine Regimen Is Correlated to Humoral Immune Response Levels., PMID:36016151
Assays for the Evaluation of the Immune Response to Marburg and Ebola Sudan Vaccination-Filovirus Animal Nonclinical Group Anti-Marburg Virus Glycoprotein Immunoglobulin G Enzyme-Linked Immunosorbent Assay and a Pseudovirion Neutralization Assay., PMID:36016099
Ligand-based design of peptide entry inhibitors targeting the endosomal receptor binding site of filoviruses., PMID:36007601
Marburg Virus VP30 Is Required for Transcription Initiation at the Glycoprotein Gene., PMID:35997284
Mining of Marburg Virus Proteome for Designing an Epitope-Based Vaccine., PMID:35911751
A Cloned Recombinant Vesicular Stomatitis Virus-Vectored Marburg Vaccine, PHV01, Protects Guinea Pigs from Lethal Marburg Virus Disease., PMID:35891170
Order: order@antibodysystem.com
Mail: support@antibodysystem.com
For research use only. Not for human or drug use.
Find out more about placing an order here
